
Opinion|Videos|March 19, 2025
ROS1 Inhibition: AE Management
Panelists discuss the management of adverse events (AEs) associated with ROS1 inhibition, emphasizing strategies for prevention, monitoring, and treatment of adverse effects.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts NDA for Daraxonrasib in Metastatic Pancreatic Cancer
2
Advanced Renal Cell Carcinoma: Tailoring Second-Line Therapy After Prior Immunotherapy
3
Teclistamab/Talquetamab Reduces Risk of Progression by 89% in R/R Multiple Myeloma
4
Updated HARMONi Analysis Shows Consistent OS Benefit With Ivonescimab in EGFRm Lung Cancer
5






























